Copyright © 2014, Evaluate Ltd, All rights reserved.

 

The seventh edition of EvaluatePharma's World Preview brings together many of our analyses to provide a top level insight, from the world's financial market, into the expected performance of the industry between now and 2020.

Record breaking new drug approvals, a hefty product pipeline and dramatically improved R&D productivity that has kept expenditure growth below sales growth proves that the industry is turning a new corner according to the latest edition of EvaluatePharma's World Preview report - view infographic here.

Key highlights in EvaluatePharma's World Preview 2014, Outlook to 2020 include:

  • Industry to grow, on average, 5.1% per year from 2013 to 2020

  • Quality of new drug approvals rose 43%, adds $24.4bn to US drug sales in 2018

  • Biologicals make up 52% of top 100 prescription & OTC drug sales in 2020

  • Oncology to set record high growth with 11.2% CAGR to 2020

  • Novartis top company by global drug sales in 2013, expected to remain through 2020

  • Teva Pharmaceutical leading generic drug maker in 2013

To download your free copy of this report, please confirm your details on the opposite form.

Every year we publish our World Preview report and make it available to industry free of charge.
Over the years, it has become a much anticipated industry standard of annual sector performance and forecasts.
We thank our readership and clients for their interest in the World Preview and for spreading the word about it.

World Preview 2014, Outlook to 2020
Worldwide Rx Sales $1 Trillion+ in 2020